ArticleNephrology (Carlton, Vic.)2025
Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New-User Active Comparator Cohort Study.
Article in Nephrology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy and Safety of Ultra-Low Starting Dose Febuxostat Titration in Male Patients With Primary Gout.International journal of rheumatic diseases · 2026Trial
- Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio-renal-metabolic risk modulation.European heart journal. Cardiovascular pharmacotherapy · 2026Review
- SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study.Diabetes, obesity & metabolism · 2026Article
- Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New-User Active Comparator Cohort Study.Nephrology (Carlton, Vic.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimHyperuricaemia, a common comorbidity among people with chronic kidney disease, is widely treated with uric acid-lowering agents such as allopurinol and febuxostat. Cardiovascular outcomes of people with chronic kidney disease receiving allopurinol or febuxostat have been controversial. The present study evaluated the risk of cardiovascular events associated with allopurinol or febuxostat treatment in people with chronic kidney disease.
methodsWe conducted a new-user active comparator cohort study using a nationwide insurance claims database in Japan. Individuals with an estimated glomerular filtration rate < 60 mL/min/1.73 m
resultsA total of 1673 and 7805 individuals were included in the allopurinol and febuxostat treatment groups, respectively. The febuxostat group had a similar incidence of the composite outcome as the allopurinol group (hazard ratio 0.93, 95% confidence interval: 0.79-1.08, p = 0.33). The hazard ratio for febuxostat compared with allopurinol treatment did not vary across different estimated glomerular filtration rate levels. The sensitivity analysis using IPTW showed similar results.
conclusionIn conclusion, no statistically significant difference in the risk of cardiovascular events was observed in people with chronic kidney disease who were newly prescribed febuxostat compared with those newly treated with allopurinol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.